Compare International Business Machines Corp (IBM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs BIO-TECHNE Corp — how do they compare? International Business Machines Corp trades at $226.86 (market cap $213.50B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: International Business Machines Corp is far larger — about 18.8× BIO-TECHNE Corp's market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and BIO-TECHNE Corp for 63 Days on average.
| IBM | TECH | |
|---|---|---|
Market Cap | $213.50B | $11.36B |
Volume | 8,908,687 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $329.23 | $72.61 |
52-Week Low | $205.77 | $43.31 |
Typical Hold Time | 88 Days | 63 Days |
Enterprise Value | $270.64B | $11.39B |
Dividend Yield | 2.98% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $220.51, down 0.35% with a bearish technical signal. The company reported strong Q1 2026 earnings beat but missed Q2 expectations. Revenue growth accelerated to $67.54B in 2025 with improved net margin of 15.52%. Recent news highlights IBM's AI platform expansion with self-hosted deployment options, while analyst consensus remains positive with a $256.69 price target representing 16% upside potential.
IBM presents a mixed investment case with solid fundamentals offset by technical weakness. The company's pivot to hybrid cloud and AI consulting shows promise with $5.5B in generative AI bookings, but faces execution risks amid cyclical mainframe weakness. Current valuation at 20.13 P/E appears reasonable given the 34.62% ROE, though near-term price pressure may persist until Q3 earnings clarity emerges.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
